Mapi, Patient-Centered Outcomes, 27 rue de la Villette, 69003, Lyon, France.
Carenity, 1 rue de Stockholm, 75008, Paris, France.
Health Qual Life Outcomes. 2018 Jul 6;16(1):134. doi: 10.1186/s12955-018-0962-3.
Patients with chronic conditions are required to take long-term treatments for their disease itself or to prevent any potential health risks. Measuring patient acceptance of their medication should help to better understand and predict patients' behavior toward treatment. This study aimed to describe the level of patient acceptance toward various long-term treatments in real life using an online patient community.
This was an observational, cross-sectional study conducted through the French Carenity platform. All Carenity patient members were invited to complete an online questionnaire including the 25-item ACCEptance by the Patients of their Treatment (ACCEPT©) questionnaire. ACCEPT© measures patient acceptance toward their medication and includes one general acceptance dimension (Acceptance/General) and six treatment-attribute specific dimensions (scores 0-100; lowest to highest acceptance): Acceptance/Medication Inconvenience, Acceptance/Long-term Treatment, Acceptance/Regimen Constraints, Acceptance/Side effects, Acceptance/Effectiveness, and Acceptance/Numerous Medications. Patients included in the analysis were treated adults experiencing any chronic diseases and who responded to at least one ACCEPT© item.
Among the 4193 patients included in the analysis, more than 270 chronic diseases were represented, amidst which 19 included more than 30 patients. Mean ACCEPT© Acceptance/General score for those 19 diseases were 61.2 (SD = 31.9) for type 1 diabetes, 59.8 (SD = 32.3) for asthma, 56.3 (SD = 34.3) for hypertension, 52.0 (SD = 32.2) for chronic obstructive pulmonary disease, 51.7 (SD = 27.0) for epilepsy, 50.1 (SD = 33.1) for bipolar disorder, 49.9 (SD = 33.1) for type 2 diabetes, 48.6 (SD = 31.6) for multiple sclerosis, 46.1 (SD = 34.5) for Crohn's disease/ulcerative colitis, 44.3 (SD = 31.5) for depression, 42.8 (SD = 31.5) for lupus, 42.3 (SD = 33.0) for arthrosis, 41.8 (SD = 32.6) for Parkinson's disease, 40.5 (SD = 32.2) for rheumatoid arthritis, 38.6 (SD = 31.7) for breast cancer, 36.4 (SD = 36.4) for myocardial infarction, 35.8 (SD = 32.0) for ankylosing spondylitis, 34.1 (SD = 32.3) for psoriasis, and 33.7 (SD = 31.7) for fibromyalgia.
This first of its kind study enabled ACCEPT© data to be collected in real life for a variety of chronic diseases. These data may help in evaluating and interpreting levels of acceptance in future studies and provide valuable insights about patient priorities and current unmet needs.
慢性病患者需要长期接受治疗来治疗疾病本身或预防任何潜在的健康风险。衡量患者对其药物的接受程度有助于更好地理解和预测患者对治疗的行为。本研究旨在通过法国的在线患者社区描述现实生活中患者对各种长期治疗的接受程度。
这是一项通过法国的 Carenity 平台进行的观察性、横断面研究。所有 Carenity 患者会员均被邀请完成一项在线问卷调查,包括 25 项患者对其治疗的接受程度(ACCEPT©)问卷。ACCEPT© 衡量患者对其药物的接受程度,包括一个总体接受维度(接受/一般)和六个治疗属性特定维度(得分 0-100;从最低到最高接受度):接受/药物不便、接受/长期治疗、接受/方案限制、接受/副作用、接受/有效性和接受/大量药物。分析中纳入的患者为接受任何慢性疾病治疗的成年患者,并对至少一项 ACCEPT© 项目做出回应。
在纳入分析的 4193 名患者中,代表了 270 多种慢性疾病,其中 19 种疾病的患者人数超过 30 人。这 19 种疾病的平均 ACCEPT© 总体接受度评分分别为:1 型糖尿病 61.2(SD=31.9)、哮喘 59.8(SD=32.3)、高血压 56.3(SD=34.3)、慢性阻塞性肺疾病 52.0(SD=32.2)、癫痫 51.7(SD=27.0)、双相情感障碍 50.1(SD=33.1)、2 型糖尿病 49.9(SD=33.1)、多发性硬化症 48.6(SD=31.6)、克罗恩病/溃疡性结肠炎 46.1(SD=34.5)、抑郁症 44.3(SD=31.5)、狼疮 42.8(SD=31.5)、骨关节炎 42.3(SD=33.0)、帕金森病 41.8(SD=32.6)、类风湿关节炎 40.5(SD=32.2)、乳腺癌 38.6(SD=31.7)、心肌梗死 36.4(SD=36.4)、强直性脊柱炎 35.8(SD=32.0)、银屑病 34.1(SD=32.3)和纤维肌痛 33.7(SD=31.7)。
这是第一项在现实生活中收集各种慢性疾病接受程度数据的研究。这些数据可能有助于在未来的研究中评估和解释接受程度,并提供有关患者优先事项和当前未满足需求的有价值的见解。